SCHEMBL3396523

SCHEMBL3396523

OCc1cnc2ccccc2c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.45
GPR3 P46089 1/20 0.45
ERN1 O75460 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
PDXK O00764 2/20 0.40
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
LMNA P02545 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394680 0.85 KDM4E (0.42) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL15045826 0.85 ERN1 (0.46) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL28115761 0.85 KDM4E (0.42) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL11069998 0.80 ERN1 (0.39) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL7850047 0.79 TLR7 (0.43) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL5013830 0.78 KDM4E (0.47) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL22721625 0.78 KDM4E (0.44) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL22744594 0.78 KDM4E (0.44) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL844114 0.78 MAOA (0.47) KDM4EGPR3ERN1LOXL2ALDH1A1
SCHEMBL11064349 0.78 ERN1 (0.44) KDM4EGPR3ERN1LOXL2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017223409-A1 DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO INFLAMMATORY BOWEL DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2017-12-28 WO claimed
WO-2023009615-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING NEUROLOGICAL INJURY OR NEUROLOGICAL DISORDERS UNIVERSITY OF CONNECTICUT (US) 2023-02-02 WO disclosed
EP-3996708-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF OPA1 FOR USE IN THE TREATMENT OF CANCER Università Degli Studi Di Padova (IT) 2022-05-18 EP disclosed
WO-2021008669-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF OPA1 FOR USE IN THE TREATMENT OF CANCER UNIVERSITA' DEGLI STUDI DI PADOVA (IT) 2021-01-21 WO disclosed
WO-2020198646-A1 INTRACELLULAR DELIVERY AND MITOCHONDRIAL TARGETING BY FLUORINATION THE TEXAS A&M UNIVERSITY SYSTEM (US) 2020-10-01 WO disclosed
EP-3697389-A1 SUSTAINED RELEASE FORMULATIONS OFCROCUS SATIVUS Council of Scientific and Industrial Research (IN) 2020-08-26 EP disclosed
EP-3484496-A1 METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES University of Southern California (US) 2019-05-22 EP disclosed
WO-2019077621-A1 SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2019-04-25 WO disclosed
WO-2018148208-A1 A HIGH THROUGHPUT 3D ASSAY FOR IMMUNE CELL AND DRUG HOMING, MIGRATION AND TUMOR CYTOTOXICITY CORNING INCORPORATED (US) 2018-08-16 WO disclosed
WO-2018013993-A1 METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2018-01-18 WO disclosed
EP-1348020-A1 AN OPTICAL METHOD FOR TESTING SENSITIVITY OF CELLS Medis El Ltd. (IL) 2003-10-01 EP disclosed
WO-2002064758-A9 AN OPTICAL METHOD FOR TESTING SENSITIVITY OF CELLS MEDIS EL LTD (IL) 2003-02-20 WO disclosed
WO-2002064758-A1 AN OPTICAL METHOD FOR TESTING SENSITIVITY OF CELLS MEDIS EL LTD. (IL) 2002-08-22 WO disclosed
US-6171786-B1 CONTACTING CELL WITH PHOSPHOINOSITOL-DEPENDENT PHOSPHOLIPASE C INHIBITOR ALONG WITH CYTOTOXIC DRUG BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS 2001-01-09 US disclosed
EP-1023067-A2 THE USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPOXIA OR IMPAIRED METABOLIC FUNCTION Eurogene Limited (GB) 2000-08-02 EP disclosed
WO-1999020260-A2 THE USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPOXIA OR IMPAIRED METABOLIC FUNCTION EUROGENE LIMITED (GB) 1999-04-29 WO disclosed
EP-0804240-A1 COMPOUNDS FOR PREVENTING MULTIDRUG RESISTANCE IN CANCER CELLS CONTAINING PROTEIN KINASE INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1997-11-05 EP disclosed
WO-1996025949-A1 COMPOUNDS FOR PREVENTING MULTIDRUG RESISTANCE IN CANCER CELLS CONTAINING PROTEIN KINASE INHIBITORS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1996-08-29 WO disclosed
US-4447435-A HYPOTENSIVE AGENTS THE BOOTS COMPANY PLC (GB) 1984-05-08 US disclosed
US-4442109-A 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension THE BOOTS COMPANY LIMITED (GB) 1984-04-10 US disclosed